Summarized by Masters of Longevity from Longevity Docs News.
GLP‑1s and aging clocks: a critical preview of a preprint that applies proteomic organ-age models to trial samples, explaining what readers will learn and the limits of inference.
Key Takeaways
- Novo Nordisk analyzed 10,052 participants from five placebo-controlled trials and found 2–4 year reductions on a proteomic heart-age clock.
- The heart clock result is driven largely by lower BNP, a heart-strain protein that semaglutide is known to reduce.
- All participants had obesity plus cardiometabolic or kidney disease, and the analysis is a non–peer-reviewed preprint funded by Novo Nordisk.
